NCT06784570

Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Zagazig University · Other Government
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

to compar levosemindan to other cardiac intropic medications that strengthen the heart in diffrent common adult heart surgery with patients with low ejection fraction(weak heart)

Detailed description

in this study show the effect of levosemindan use during coronary artery surgery ,heart valve surgery and combined coronary and valve surgery in comparison to other traditional medications with patients with low ejection fraction(weak heart)

Conditions

• Cardiac Surgery
• Low Ejection Fraction

Interventions

Type	Name	Description
DRUG	levosemindan	In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.
DRUG	adrenaline,noreadrenaline,dopamine and doputamine	adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9

Timeline

• Start date: 2021-01-01
• Primary completion: 2024-03-01
• Completion: 2024-08-01
• First posted: 2025-01-20
• Last updated: 2025-01-20

Locations

1 site across 1 country: Egypt